Anthos Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In Bostondedicated To Developing Innovative Therapies For High Risk Cardiovascular Patientsfounded In 2019 Through A Partnership Between Blackstone Life Sciences And Novartisthe Company Focuses On Addressing Unmet Medical Needs In Cardiovascular Diseasesin April 2025Anthos Was Acquired By Novartis In A Deal Valued At Up To $3 1 Billion The Company S Flagship Productabelacimabis A Biologic Molecule Designed To Inhibit Factor Xia Key Player In Blood Clottingabelacimab Is Currently In Phase 3 Clinical Development For Several Indicationsincluding The Prevention Of Stroke And Systemic Embolism In Patients With Atrial Fibrillationas Well As Cancer Associated Thrombosisanthos Therapeutics Aims To Provide Safer Anticoagulation Options That Minimize Bleeding Risks Compared To Traditional Treatmentsultimately Improving Patient Outcomes In The Cardiovascular Space
